The UCLA CFAR Cytometry Core Facility (CCF) provides state-of-the-art instrumentation and expertise at an affordable cost to UCLA researchers needing flow cytometry, ImmunoSpot and Luminex technology The CCF leverages additional funding from the UCLA Jonsson Comprehensive Cancer Center and the School of Medicine's Dean's office to stay cost effective. Dr. Jamieson, the Director since 2000, is an accomplished immunologist and is available for consultation to users. Ms. Schmid, the manager of the facility since 1988, is responsible for the CCF's daily operation and assists Dr. Jamieson with long-term planning. Ms. Schmid is an expert flow cytometrist, well known for her development of flow cytometry methods and her pivotal role in establishing biosafety guidelines for cell sorting. In 2001, the CCF began offering ELISpot instrumentation and Dr. Uittenbogaart joined the leadership as Co-Director in order to lend her expertise in this technology. Dr. Uittenbogaart is a noted cellular immunologist with extensive expertise in cytokine measurements and she is also available for consultation. Instrumentation within the CCF has been extensively upgraded during the reporting period and now includes one 3-color FAC Scan, a 5- color FACScan, one FACSCalibur, two LSR II analyzers, one with 3, and the other with 5 lasers, two Aria II high-speed cell sorters, one with 3, and the other with 4 lasers, a 3-laser Arial ll to be enclosed into a biocontainment hood in June 2012, a RoboSep magnetic cell separator, an ImmunoSpot/BioSpot analyzer, and a Bio-Plex 200 HTF instrument. There is one-off line computer for analyzing flow cytometry data, and five analysis stations available for use within the ImmunoSpot/BioSpot portion of the Core. The CCF is centrally located and is responsible for procurement, daily calibration, maintenance and repair of all instrumentation. CCF personnel have over 130 years of combined flow cytometry experience and 51 years of experience in measuring cytokines. Expertise is available through one-on-one consultation, classes, a website, and poster presentations. Ms. Schmid and Dr. Uittenbogaart are also available to work with researchers to adapt or develop assays to enable investigators to pursue research questions in novel ways. Workshops, seminars, and utilization of new assays ensure that researchers remain on the cutting edge of cytometry without investing their own funds or staff time. During the reporting period a total of 328 research laboratories used the CCF. 53 of those were headed by CFAR/HIV investigators, representing 33% of use which documents the role of the CCF in enhancing HIV research at UCLA its and its contribution to improving the health of HIV-infected patients.

Public Health Relevance

There is no vaccine or permanent cure that can stop the continued spread of HlV-1 and HlV-2. The Cytometry Core Facility offers a critical, cost-effective, resource for UCLA investigators seeking to develop vaccines and therapeutic strategies that will prevent new infections and allow eradication from already infected hosts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI028697-25
Application #
8631024
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
25
Fiscal Year
2014
Total Cost
$230,563
Indirect Cost
$33,800
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Qi, Hangfei; Chu, Virginia; Wu, Nicholas C et al. (2017) Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 114:2018-2023
Graham, Nicholas A; Minasyan, Aspram; Lomova, Anastasia et al. (2017) Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol 13:914
Castaneda, Julie T; Harui, Airi; Roth, Michael D (2017) Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation. J Neuroimmune Pharmacol 12:544-554
Harawa, Nina T; Holloway, Ian W; Leibowitz, Arleen et al. (2017) Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. AIDS 31:739-740
Richardson-Harman, Nicola; Parody, Robert; Anton, Peter et al. (2017) Analytical Advances in the Ex Vivo Challenge Efficacy Assay. AIDS Res Hum Retroviruses 33:395-403
Foo, Suan-Sin; Chen, Weiqiang; Chan, Yen et al. (2017) Asian Zika virus strains target CD14+ blood monocytes and induce M2-skewed immunosuppression during pregnancy. Nat Microbiol 2:1558-1570
Bergstrom, K; Fu, J; Johansson, M E V et al. (2017) Core 1- and 3-derived O-glycans collectively maintain the colonic mucus barrier and protect against spontaneous colitis in mice. Mucosal Immunol 10:91-103
Farmer, Shu; Mindry, Deborah; Comulada, W Scott et al. (2017) Mobile Phone Ecological Momentary Assessment of Daily Stressors Among People Living With HIV: Elucidating Factors Underlying Health-Related Challenges in Daily Routines. J Assoc Nurses AIDS Care 28:737-751
Tan, Diane; Holloway, Ian W; Gildner, Jennifer et al. (2017) Alcohol Use and HIV Risk Within Social Networks of MSM Sex Workers in the Dominican Republic. AIDS Behav 21:216-227
Bristow, Claire C; Lee, Sung-Jae; Severe, Linda et al. (2017) Attributes of diagnostic tests to increase uptake of dual testing for syphilis and HIV in Port-au-Prince, Haiti. Int J STD AIDS 28:259-264

Showing the most recent 10 out of 865 publications